Journal article · 2022

Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles

Jiangcheng Xu, Yang Liu, Jing Wang, Fan Fei, Haitao Gu, Lanxin Zhang, Jun Wang, Song Z. Ding, Ailong Guo, Hongjuan Zhang, Kaixuan Su, Jiaojiao Su and 5 more

Cancer Research, 82(12_Supplement), 5605 · Published 15 June 2022 · DOI 10.1158/1538-7445.am2022-5605

View at the publisherCite this paper

In brief

“Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles” is a 2022 journal article by Jiangcheng Xu and 16 co-authors, published in Cancer Research. OpenAlex counts 1 citations as of 18 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
1
Most cited in
2026 (1)
Authors
17

Abstract

4-1BB (CD137, TNFSF9) is a promising co-stimulatory signaling mediator of T cells and NK cells, and agonistic monoclonal antibodies targeting 4-1BB are under clinical investigations aiming to observe sufficient and prolonged anti-tumor efficacy. However, these trials have resulted in limited efficacy or safety, and different bispecific approaches are being explored to improve the profiles. BH3120… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Xu, J., Liu, Y., Wang, J., Fei, F., Gu, H., Zhang, L., Wang, J., Ding, S. Z., Guo, A., Zhang, H., Su, K., Su, J., Li, L., Cai, J., Zhang, A.-H., Liu, J., & Lee, K. (2022). Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles. Cancer Research, 82(12_Supplement), 5605. https://doi.org/10.1158/1538-7445.am2022-5605

MLA 9

Xu, Jiangcheng, et al. “Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles.” Cancer Research, vol. 82, no. 12_Supplement, 2022, p. 5605. https://doi.org/10.1158/1538-7445.am2022-5605.

Chicago

Xu, Jiangcheng, Yang Liu, Jing Wang, Fan Fei, Haitao Gu, Lanxin Zhang, Jun Wang, et al. 2022. “Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles.” Cancer Research 82 (12_Supplement): 5605. https://doi.org/10.1158/1538-7445.am2022-5605.

Harvard

Xu, J. et al. (2022) ‘Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles’, Cancer Research, 82(12_Supplement), p. 5605. doi:10.1158/1538-7445.am2022-5605.

IEEE

J. Xu et al., “Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles,” Cancer Research, vol. 82, no. 12_Supplement, p. 5605, 2022, doi: 10.1158/1538-7445.am2022-5605.

BibTeX

@article{xu2022abstract,
  title     = {{Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles}},
  author    = {Xu, Jiangcheng and Liu, Yang and Wang, Jing and Fei, Fan and Gu, Haitao and Zhang, Lanxin and Wang, Jun and Ding, Song Z. and Guo, Ailong and Zhang, Hongjuan and Su, Kaixuan and Su, Jiaojiao and Li, Lijuan and Cai, Jingmei and Zhang, Ai-Hong and Liu, Jiawang and Lee, Kyoungwoo},
  journal   = {Cancer Research},
  year      = {2022},
  volume    = {82},
  number    = {12_Supplement},
  pages     = {5605},
  doi       = {10.1158/1538-7445.am2022-5605},
  url       = {https://doi.org/10.1158/1538-7445.am2022-5605}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • bispecific antibodies
  • 4-1BB
  • PD-L1
  • costimulation
  • agonistic monoclonal antibody
  • immune checkpoint inhibitor combination
  • antitumor efficacy
  • safety profile

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Xu, J., Liu, Y., Wang, J., Fei, F., Gu, H., Zhang, L., Wang, J., Ding, S. Z., Guo, A., Zhang, H., Su, K., Su, J., Li, L., Cai, J., Zhang, A.-H., Liu, J., & Lee, K. (2022). Abstract 5605: BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles. Cancer Research, 82(12_Supplement), 5605. https://doi.org/10.1158/1538-7445.am2022-5605

How many times has this paper been cited?

1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Jiangcheng Xu, Yang Liu, Jing Wang, Fan Fei, Haitao Gu, Lanxin Zhang, Jun Wang, Song Z. Ding, Ailong Guo, Hongjuan Zhang, Kaixuan Su, Jiaojiao Su and 5 more.

What is the DOI of this paper?

10.1158/1538-7445.am2022-5605, permanently at https://doi.org/10.1158/1538-7445.am2022-5605. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.